Compare ARCO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | TNGX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2011 | N/A |
| Metric | ARCO | TNGX |
|---|---|---|
| Price | $7.40 | $9.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.60 | ★ $12.50 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 69.06 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $4,555,936,000.00 | $66,501,000.00 |
| Revenue This Year | $6.39 | $53.01 |
| Revenue Next Year | $7.36 | N/A |
| P/E Ratio | $6.42 | ★ N/A |
| Revenue Growth | 1.21 | ★ 53.29 |
| 52 Week Low | $6.51 | $1.03 |
| 52 Week High | $8.52 | $11.20 |
| Indicator | ARCO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 48.66 |
| Support Level | $7.45 | $8.89 |
| Resistance Level | $7.80 | $10.22 |
| Average True Range (ATR) | 0.18 | 0.62 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 38.52 | 9.22 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.